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Abstract 
As parasites, Plasmodium species depend upon their host for survival. During the blood stage of their life-cycle para-
sites invade and reside within erythrocytes, commandeering host proteins and resources towards their own ends, and 
dramatically transforming the host cell. Parasites aptly avoid immune detection by minimizing the exposure of para-
site proteins and removing themselves from circulation through cytoadherence. Erythrocytic disorders brought on by 
host genetic mutations can interfere with one or more of these processes, thereby providing a measure of protection 
against malaria to the host. This review summarizes recent findings regarding the mechanistic aspects of this protec-
tion, as mediated through the parasites interaction with abnormal erythrocytes. These novel findings include the 
reliance of the parasite on the host enzyme ferrochelatase, and the discovery of basigin and CD55 as obligate eryth-
rocyte receptors for parasite invasion. The elucidation of these naturally occurring malaria resistance mechanisms is 
increasing the understanding of the host-parasite interaction, and as discussed below, is providing new insights into 
the development of therapies to prevent this disease.
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Background
The clinical symptoms of malaria occur during the blood 
stage of Plasmodium’s life cycle. Safely ensconced within 
the host erythrocyte, parasites develop and replicate 
whilst concealing their presence from the immune sys-
tem. After consuming the contents of the host cell, and 
growing and multiplying to fill the available space, the 
progeny egress as merozoites, and, after briefly existing 
extracellularly, invade fresh erythrocytes, continuing the 
cycle of growth and proliferation. This cycle depends on 
an elaborate interplay between host and parasite proteins, 
which has been meticulously established over thousands 
of years of co-evolution. As such, any perturbations to 
the composition or arrangement of proteins in the host 
erythrocyte can potentially impede the parasite’s growth 
and survival, and thereby increase the resistance of the 
host to infection. Indeed, abnormalities of the erythro-
cyte are relatively common, especially in populations 
residing in malaria-endemic regions, consistent with the 
positive selection for these conditions. The mechanistic 
basis for protection against malaria is partly understood 
in some abnormalities; parasite invasion and intraeryth-
rocytic development are often affected. However, recent 
studies have revealed a more complex picture, with many 
conditions sharing multiple and over-lapping pathways 
that advantage the host. The understanding of the par-
asite-erythrocyte interaction is also being challenged as 
novel and highly intimate relationships between the para-
site and its host cell are discovered. This review will sum-
marize the current knowledge regarding Plasmodium’s 
interaction with abnormal host erythrocytes, the mecha-
nisms by which these abnormalities can inhibit the blood 
stage of Plasmodium’s life cycle, and the implications of 
these findings for malaria treatment.
Open Access
*Correspondence:  patrick.lelliott@anu.edu.au 
John Curtin School of Medical Research, Australian National University, 
Canberra, ACT, Australia
Page 2 of 15Lelliott et al. Malar J  (2015) 14:289 
Genetic erythrocyte abnormalities and malaria 
susceptibility
Erythrocytes have a limited lifespan (120  days in 
humans) and, therefore, must be continually replenished 
in a process known as erythropoiesis. In this process hae-
matopoietic stem cells replicate and differentiate into 
erythroblasts, and following expulsion of their nucleus 
and most organelles, develop into reticulocytes. Reticulo-
cytes are released from the bone marrow into the blood-
stream and following further depletion of organelles and 
intracellular RNA, become mature erythrocytes. There 
are a number of erythrocyte disorders that result from 
mutations in the genes expressed during erythropoie-
sis; many are highly prevalent, particularly in popula-
tions with a long history of malaria exposure. It was first 
observed nearly 70  years ago that people with ‘sickled’ 
erythrocytes were less likely to suffer from malaria [1]. 
This condition is common in various West and Cen-
tral African ethnicities. Now known as sickle cell trait, 
this and many other erythrocytic disorders, have been 
strongly associated with reduced malaria susceptibility. 
In fact, mutations causing erythrocyte abnormalities are 
the most commonly observed genetic traits in humans 
[2]. Genetic mutations associated with malaria resistance 
have been extensively reviewed previously [3–5]; a sum-
mary of known erythrocytic genetic disorders and their 
association with malaria susceptibility is given in Table 1.
Mechanisms by which erythrocyte abnormalities 
protect against malaria
Early studies towards identifying malaria protective mech-
anisms imparted by erythrocyte abnormalities largely 
focussed on the ability of the parasite to invade and grow 
within erythrocytes. These studies were facilitated by an 
in  vitro culturing system for Plasmodium falciparum, 
which allowed researchers to easily compare between 
erythrocytes obtained from subjects with various genetic 
conditions. As the understanding of malaria pathogenesis 
was expanded, the importance of factors such as cytoad-
herence and the ability of the immune system to detect 
parasitized erythrocytes was also recognized. Studies then 
addressed how erythrocyte abnormalities could affect 
not only parasite invasion and growth under in vitro con-
ditions, but also their effects in  vivo, and how this may 
influence host resistance to malaria infection. This review 
considers how specific erythrocyte abnormalities affect 
four distinct features of the parasite-host interaction. 
Namely, merozoite invasion, parasite growth, cytoadher-
ence, and erythrocyte senescence.
Merozoite invasion of the erythrocyte
The brief interval between parasite egress and reinvasion 
of a new erythrocyte has long been considered a potential 
weak point in its blood stage lifecycle. In vitro studies 
have shown that P. falciparum merozoites are exposed for 
approximately 2 min from egress to reinvasion, while the 
actual invasion event is completed in less than 30  s [6]. 
During this period the parasite is particularly susceptible 
to host recognition and attack mechanisms, due to the 
potential for direct contact with opsonins and immune 
cells; the parasite also becomes nonviable if it fails to 
invade a new cell [7]. Consequently, any disruption to 
the invasion pathway is beneficial to the host, and several 
abnormalities are known to directly affect this process.
There are several well-characterized genetic mutations 
in erythrocyte membrane proteins that are associated 
with impaired merozoite invasion. For example, African 
populations carry a highly prevalent single nucleotide 
polymorphism (SNP) in the promoter region controlling 
expression of the Duffy antigen receptor for chemokines 
gene (DARC or Duffy; rs2814778). The SNP prevents 
erythrocytic expression and results in the Duffy-nega-
tive blood phenotype [8]. Duffy is a ligand for a P. vivax 
merozoite protein called the Duffy-binding protein 
(PvDBP) and the Duffy-PvDBP interaction is essential for 
merozoite invasion of the erythrocyte [9, 10]. Therefore, 
Duffy-negative individuals are protected against Plasmo-
dium vivax infection and in areas of Africa with a high 
incidence of this SNP, P. vivax infection is virtually non-
existent [11, 12]. In contrast P. vivax is common in other 
malaria endemic areas where populations do not carry 
this polymorphism (Asia and South America) [12, 13]. 
However, complete protection due to this polymorphism 
has been questioned recently by observations of P. vivax 
infection in Duffy negative individuals in several stud-
ies [14–16]. In contrast to P. vivax, P. falciparum mero-
zoites utilize several redundant invasion pathways and 
different host ligands. In 1977, Miller et al. [17] reported 
that erythrocytes from individuals with the rare En (a−) 
mutation were resistant to P. falciparum merozoite inva-
sion. En (a−) erythrocytes lack Glycophorin A (GYPA), 
highlighting a possible role for this protein as a para-
site ligand. Indeed, GYPA is now known to be a bind-
ing partner of P. falciparum erythrocyte binding antigen 
175 (PfEBA-175) [18, 19], and more recently, was found 
to bind to merozoite surface protein 1 (PfMSP1) [20]. 
In the later study, the erythrocyte surface band 3-GYPA 
complex was shown to be essential for invasion by both 
P. falciparum and the rodent malaria parasite, Plasmo-
dium yoelii. Mutations in other erythrocyte glycophorins 
(GYPB and GYPC) are common in endemic malaria pop-
ulations, and recent studies have demonstrated compa-
rable importance for these proteins in parasite invasion. 
The P. falciparum protein erythrocyte-binding ligand-1 
(PfEBL-1) binds to GYPB [21, 22], while GYPC is a recep-
tor for erythrocyte binding antigen 140 (PfEBA-140) [23]. 
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Antibodies against the binding domains of both PfEBL-1 
and PfEBA-140 inhibit merozoite invasion, while eryth-
rocytes deficient in either GYPB (blood group S-s-U-), or 
GYPC (Gerbich negativity) are resistant to invasion [21–
24]. Erythrocyte expressed complement receptor 1 (CR1) 
is also a demonstrated receptor for the P. falciparum mer-
ozoite protein PfRh4, with antibodies against CR1, as well 
as soluble CR1 protein, preventing invasion [25, 26]. This 
may partially explain the enhanced malaria resistance 
exhibited by individuals with inherited mutations result-
ing in CR1 deficiency [27]. Recently, two high throughput 
screening approaches were developed to identify novel 
host binding partners of merozoite proteins involved in 
invasion. The first utilized the Avidity-based extracellular 
interaction screen (AVEXIS) to identify binding interac-
tions between erythrocyte and merozoite proteins [28]. 
This led to the discovery of a single definitive interac-
tion between the host protein basigin and P. falciparum 
reticulocyte-binding protein homologue 5 (PfRH5). Anti-
body blocking studies demonstrated that this interac-
tion is essential for invasion by all P. falciparum strains 
tested to date [28, 29], and erythrocytes expressing nat-
urally occurring mutations in basigin (known as the Ok 
blood group antigen) also prevented parasite invasion 
[28]. This host-parasite receptor ligand interaction also 
appears to be important in clinical disease based on the 
Table 1 Erythrocyte disorders and the possible mechanisms by which they protect against malaria
↓ Decreased, ↑increased. “Malaria susceptibility” refers to evidence for an association with reduced risk of severe or uncomplicated malaria. “Growth” refers to the 
ability of an individual parasite to replicate and egress from the erythrocyte. Studies performed with P. falciparum unless otherwise indicated.
Erythrocyte dis-
order
Malaria suscepti-
bility
Invasion Growth Cytoadherence Erythrocyte  
senescence
References
Sickle cell trait 
(HbAS)
↓ ↓ (Low oxygen) or 
normal
↓ (Low oxygen) ↓ ↑ [61, 68–70, 104, 122, 
125]
Sickle cell disease 
(HbSS)
↓ ↓ (Low oxygen) or ↑ ↓ (Low oxygen) ↓ Unknown [61, 70, 104]
HbAC ↓ Normal ↓ ↓ Unknown [68, 69, 105]
HbCC ↓ Normal ↓ ↓ Unknown [61–63, 69, 105]
HbAE ↓ ↓ Normal Unknown Unknown [178]
HbEE Unclear Normal ↓ or normal Unknown Unknown [64]
α+ thalassaemia 
(−α/αα)
↓ Normal ↓ (High oxygen) ↓ Normal [27, 65, 106]
α0 thalassaemia (−/
αα)
↓ ↓ or normal ↓ or normal ↓ Unknown [106]
HbH thalassaemia 
(−/−α)
↓ ↓ or normal ↓ ↓ ↑ [66, 67, 106, 122]
β0 thalassaemia 
(−/β)
Unclear Normal ↓ (High oxygen) Unknown ↑ [65, 122]
G6PD deficiency ↓ Normal ↓or normal Unknown ↑ [3, 129–131]
PK deficiency Unknown ↓ Normal Unknown ↑ [133]
Duffy negativity ↓ (In P. vivax) ↓ (in P. vivax) Normal Unknown Unknown [9–11]
ABO blood group ↓ (O type) ↑
(A and AB type)
Normal Normal Unknown ↑ (For O type) [135, 136]
CR1 deficiency Unclear ↓ Unknown Unknown Unknown [25–27]
GYPA deficiency Unknown ↓ Unknown Unknown Unknown [17, 18, 20]
GYPB deficiency Unknown ↓ Unknown Unknown Unknown [21, 24]
GYPC deficiency Unclear ↓ Unknown Unknown Unknown [23]
Basigin deficiency Unknown ↓ Unknown Unknown Unknown [28]
CD55 deficiency Unknown ↓ Unknown Unknown Unknown [31]
Southeast Asian 
ovalocytosis (SAO)
↓ ↓ Normal ↑ Unknown [37, 45, 48, 49, 51, 
107]
Hereditary ellipto-
cytosis
Unknown ↓ or normal ↓ Unknown Unknown [54, 58, 59]
Hereditary sphero-
cytosis
Unknown ↓ or normal ↓ Unknown Unknown [57, 59]
Erythropoietic proto-
porphyria
Unknown Unknown ↓ Unknown Unknown [84]
Page 4 of 15Lelliott et al. Malar J  (2015) 14:289 
findings that naturally acquired antibodies to PfRH5 are 
associated with improved outcomes to infection [30]. 
Another screening approach has utilized in  vitro differ-
entiated human erythroid cells in conjunction with short 
hairpin RNA (shRNA) libraries to target and screen for 
erythroid-expressed proteins necessary for P. falciparum 
merozoite invasion. As well as corroborating a require-
ment for basigin and CR1 in invasion, a novel interac-
tion involving erythrocyte CD55, also known as Decay 
accelerating factor (DAF), was found to be essential for 
the invasion process. The requirement for this interac-
tion was confirmed utilizing naturally-occurring CD55 
null erythrocytes, which were refractory to invasion by 
several P. falciparum strains, including clinical isolates 
[31]. Interestingly, polymorphisms in CD55 are enriched 
in populations with historical exposure to malaria [32, 
33], indicating a possible selection pressure on this gene. 
Importantly, the identification of host cell receptor-para-
site ligand interactions has produced several possible tar-
gets for vaccine or therapeutic development.
The erythrocyte membrane is supported by an under-
lying network of proteins called the cytoskeleton, which 
provides the cell with structure and deformability, and 
serves as an anchoring point for membrane proteins. 
Hereditary elliptocytosis and hereditary spherocytosis 
are conditions caused by mutations in genes encoding 
cytoskeletal proteins, including alpha spectrin, beta spec-
trin, ankyrin, band 3 and protein 4.1, which affect mol-
ecule conformation or abundance. Mutations in genes 
encoding some of these proteins have been associated 
with increased protection against infection or severe 
forms of malaria. A well-known example is Southeast 
Asian ovalocytosis (SAO), which is caused by mutations 
in the gene encoding band 3. Band 3 is a transmembrane 
protein that normally exists as a dimer or tetramer and 
interacts with both the cytoskeleton and cell membrane; 
it also functions as an anion transporter. In SAO, muta-
tions disrupt the anion transporter activity and result in 
the formation of large-sized aggregates [34–36], resulting 
in increased cell membrane rigidity [37–39], oval shaped 
cell morphology, reduced band 3 mobility in the mem-
brane [40–42], and decreased expression of surface anti-
gens [43, 44]. Homozygous inheritance of SAO-causing 
band 3 mutations results in embryonic lethality, however 
heterozygosity is associated with a marked protection 
against severe P. falciparum malaria, particularly cerebral 
malaria [45, 46]. Despite the fitness cost, frequencies of 
these mutations are remarkably high some populations, 
particularly those residing in Papua New Guinea [47]. 
There is strong evidence that P. falciparum merozoite 
invasion of SAO erythrocytes is impaired, which could 
plausibly explain the reduced malaria susceptibility con-
veyed by this condition [37, 39, 48, 49]. Mechanistic 
explanations variously include increased membrane 
rigidity, direct interference with parasite/band 3 binding 
[37–39, 50, 51], a loss or reduction of merozoite ligands, 
such as GYPA (which forms a complex with band 3) [20, 
43, 44], and reduced band 3 mobility [52, 53]. Interest-
ingly, cells with artificially inhibited band 3 mobility 
also exhibit reduced rates of merozoite invasion [53]. 
Erythrocytes from patients with other forms of heredi-
tary elliptocytosis and spherocytosis have shown more 
variable, and sometimes inconsistent effects on para-
site invasion. Erythrocytes deficient in protein 4.1 are 
reported to be less vulnerable to parasite invasion [54], 
which could possibly be explained by a secondary defi-
ciency of GYPC (90% less in protein 4.1 deficient cells), 
although the role of GYPC as a parasite ligand was not 
investigated in this study. Utilizing a recently developed 
method for measuring merozoite invasion in  vivo [55, 
56], a study in mice carrying a mutation in ankyrin-1 
(Ank1) reported reduced rates of erythrocyte invasion 
by Plasmodium chabaudi merozoites; this coincides with 
increased resistance and reduced parasitaemia reported 
in these mice [57]. Investigations of hereditary sphero-
cytosis caused by mutations in alpha spectrin have also 
reported reduced merozoite invasion [58], however these 
studies are contradictory and the exact effects of these 
conditions remain inconclusive [59].
Overall, the disruption of parasite invasion is an obvi-
ous and testable mechanism by which erythrocyte dis-
orders can protect the host against malaria infection. 
This is most evident for mutations that disrupt a specific 
parasite-erythrocyte binding interaction. Erythrocytes 
with structural abnormalities, such as spherocytosis and 
ovalocytosis, may also present the merozoite with a less 
than ideal substrate for invasion, however the mecha-
nisms are difficult to establish, and findings are less 
consistent.
Intraerythrocytic growth
After gaining entry into an erythrocyte the Plasmodium 
parasite must dramatically remodel the host cell cyto-
plasm and membrane in order to grow, replicate, and 
eventually egress. The success of the parasite at this stage 
depends on several factors; the ability to digest haemo-
globin, establishment of pathways to import nutrients, 
export waste products and traffic synthesized proteins 
around the cell, scavenging of host proteins, and, finally, 
effective dissolution of the cell membrane during egress.
There are five types of haemoglobinopathies found at 
high frequencies in both extant and historically malaria 
afflicted populations, and each has been implicated 
to varying degrees in perturbing the intraerythrocytic 
development and growth of Plasmodium. Three of these 
involve single amino acid substitutions in the beta globin 
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chain of haemoglobin; sickle cell (HbS, β6Glu to Val, 
rs334), haemoglobin C (HbC, β6Glu to Lys, rs33930165), 
and haemoglobin E (HbE, β26Glu to Lys, rs33950507). 
The remaining two types of haemoglobinopathies, alpha 
and beta thalassaemia, arise due to reduced expression 
of the alpha and beta globin chains of haemoglobin, 
respectively, caused by various polymorphisms in the 
genes encoding these proteins. Impaired parasite growth 
in these cells (here defined specifically as the ability of 
an individual parasite to grow, replicate and produce 
new viable merozoites) has been frequently reported, 
although studies are often contradictory (for review see 
Taylor et al. [60]). An impairment in parasite growth has 
been consistently observed in homozygous haemoglo-
bin C (HbCC) erythrocytes [61–63], which is proposed 
to be caused by spontaneous degradation of parasites 
in a subset of damaged mutant cells with an increased 
haemoglobin concentration [63]. Parasite growth is also 
impaired in homozygous haemoglobin E (HbEE) erythro-
cytes [64]. Two early studies by Friedman et al. [61, 65] 
indicated a role for oxygen tension in parasite growth in 
heterozygous HbS (HbAS or sickle cell trait), homozy-
gous HbS (HbSS or sickle cell disease), alpha thalassae-
mia trait, and beta thalassaemia minor. Under low oxygen 
tension parasitized HbAS and HbSS cells underwent 
sickling and growth was attenuated. Conversely, in tha-
lassaemic cells growth impairment occurred only under 
high oxygen tension. In the more severe form of alpha 
thalassaemia, known as haemoglobin H (HbH), a growth 
impairment has been consistently observed, however 
the mechanism remains unknown [66, 67]. More recent 
studies have suggested two novel mechanisms of para-
site growth impairment in haemoglobinopathies. A study 
by Cyrklaff et  al. [68] describes a process whereby host 
actin filaments are utilized by the parasite in developing 
Maurer’s clefts. In HbAS and heterozygous haemoglo-
bin C (HbAC) cells, host actin filaments are dispersed 
further into the erythrocyte cytosol and are significantly 
longer than in normal cells, consequently, during remod-
elling by the parasite they fail to support the formation 
of normal Maurer’s clefts. The authors suggest this may 
be due to interference from oxidized forms of haemo-
globin present in these cells, known as haemichromes. 
More recently, studies using a conditional protein export 
system indicated that the trafficking of parasite proteins 
across the parasitophorous vacuole is delayed and occurs 
at a slower rate in HbAS, HbAC, and HbCC erythrocytes, 
leading to reduced levels of parasite proteins in the eryth-
rocyte cytosol and membrane [69]. Another study by La 
Monte et  al. [70] proposes an entirely different mecha-
nism whereby specific host micro RNAs, which are more 
abundant in HbAS and HbSS cells, are translocated into 
the parasite and fuse with parasite mRNA, inhibiting 
normal translation of parasite proteins. While the poten-
tial role of parasite protein trafficking and micro RNA in 
HbE and thalassaemia has not been investigated, it seems 
quite plausible that these may be a common mechanism 
explaining the reduced malaria susceptibility provided by 
these erythrocyte disorders.
Plasmodium falciparum growth is also impaired in 
spherocytotic and elliptocytotic erythrocytes. Schulman 
et  al. [59] report that the degree of growth impairment 
correlates with the extent of spectrin deficiency or spec-
trin dimer content in spherocytotic and elliptocytotic 
erythrocytes respectively. This growth inhibition was 
not due to metabolic effects or haemolysis, and instead 
seems to be caused exclusively by the abnormal cytoskel-
eton. These results were supported by a later study, where 
reduced parasite growth in elliptocytotic erythrocytes 
was observed [54]. Finally, mice carrying a heterozygous 
mutation in Ank1, which results in severe spherocytosis 
in homozygotes, have an increase in terminal deoxynu-
cleotidyl transferase dUTP nick end labelling (TUNEL) 
of intraerythrocytic parasites [57]. TUNEL staining indi-
cates the presence of fragmented DNA, which has been 
associated with reduced growth and is likely an indica-
tion of parasite death [71]. Growth impairment in these 
conditions could be due to disruptions in interactions 
between parasite proteins and the host cytoskeleton, sev-
eral of which have been well documented [72–76].
While haem biosynthesis only occurs in erythroid pro-
genitor cells, small amounts of the enzymes used in the 
biosynthetic pathway remain in the mature erythrocyte 
[77, 78]. It has been hypothesized that the parasite may 
hijack these enzymes for its own haem synthesis, a notion 
driven by the fact that the parasite haem biosynthesis 
pathway is dispensable [79, 80], and that a number of 
these host enzymes are imported into the parasite during 
growth [81–83]. A recent study of ferrochelatase (Fech), 
which catalyses the final step in haem biosynthesis, indi-
cates the parasite may largely depend on the erythrocyte 
enzyme. Fech-deficient mice (homozygous for a fer-
rochelatase knockdown mutation) were more resistant 
to P. chabaudi infection with parasite growth reduced, 
while P. falciparum growth was significantly impaired in 
cultures using Fech deficient-erythrocytes from patients 
with erythropoietic protoporphyria. Furthermore, eryth-
rocytes in which ferrochelatase was inhibited pharmaco-
logically also impeded parasite growth [84]. Another line 
of evidence indicates that the parasite utilizes the host 
kinases PAK-1 and MEK-1 to facilitate growth. They are 
specifically activated in infected erythrocytes and highly 
specific PAK-1 and MEK-1 inhibitors are potent inhibi-
tors of parasite growth [85]. A different study has dem-
onstrated a requirement for erythrocyte calpain-1 during 
parasite egress. Depletion or pharmaceutical inhibition 
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of the enzyme prevented this stage of the parasite growth 
cycle [86]. Calpain-1 activation is likely initiated through 
a host signalling pathway involving protein kinase C 
(PKC). It is postulated that parasite GPCR ligands over-
stimulate host GPCRs, leading to G-protein alpha-q 
mediated activation of PKC, which in turn compromises 
the erythrocyte cytoskeleton through the phospho-
rylation of adducin and activation of the cation channel 
TRPC6. Rapid calcium influx through TRPC6 leads to 
the activation of calpain-1, which facilitates breakdown 
of the cell membrane and parasite egress. In support of 
a central role of PKC in this process, inhibitors of PKC 
show strong antimalarial activity during in  vivo rodent 
malaria infection [87]. Finally, while not directly proven 
to be required for parasite growth, the host antioxidant 
enzymes superoxide dismutase [88] and peroxiredoxin-2 
[89] are imported into the parasite and they retain their 
biological activity. In the case of peroxiredoxin-2, more 
than half of the parasite’s peroxide degradation capacity 
was estimated to derive from the host enzyme [89].
Cytoadherence and splenic clearance of parasitized 
erythrocytes
The Plasmodium parasite distinguishes itself from most 
other pathogens in that its target cell, at least in mam-
mals, is enucleate and lacks the intracellular pathogen 
sensing machinery present in most other cells of the 
body. The host must therefore rely on immune mecha-
nisms that allow extracellular recognition (and removal) 
of parasitized cells.
The spleen is responsible for the removal of abnormal 
and senescent erythrocytes, and is also a major compo-
nent in the host recognition and clearance of parasitized 
cells [90]. It is a highly vascularized organ comprising of 
inter-endothelial slits through which all erythrocytes in 
circulation pass (on average once every 100–200  min) 
[90, 91]. Erythrocytes not sufficiently deformable to 
pass through the slits are retained and are phagocyt-
ized by macrophages [92–94]. As the Plasmodium para-
site grows within the erythrocyte, the cell deformability 
decreases [95–98], so that it may similarly be retained by 
the spleen and removed; even relatively immature ring-
stage parasitized cells undergo an appreciable degree 
of splenic retention [96, 99]. However, parasites avoid 
splenic retention by expressing molecules that promote 
cell adhesion, both to other erythrocytes (called roset-
ting) and to endothelial cells. This results in the so-called 
sequestering of parasitized cells within microvasculature 
tissue beds, where they can continue to grow and repli-
cate in relative isolation. In the case of P. falciparum, the 
adhesive properties are largely imparted by the interac-
tion of PfEMP proteins with endothelial cell surface mol-
ecules such as ICAM1 and CD36 [100] and chondroitin 
sulphate in the placental vasculature [101]. Although the 
pathological consequences of P. falciparum sequestra-
tion are still debated (for review see Rowe et  al. [102]), 
binding of infected cells to the endothelium has been 
demonstrated to promote coagulation, endothelial dys-
function, and inflammation, ultimately causing blood 
vessel obstruction, while sequestration in the brain 
microvasculature is linked to the life threatening cerebral 
malaria syndrome [103].
Several studies have shown that P. falciparum para-
sitized HbAS [104] [69], HbSS [104], HbAC [105] [69], 
HbCC [105] [69], and alpha thalassaemic [106] eryth-
rocytes do not bind as readily to human microvascu-
lar endothelial cells in  vitro (compared with parasitized 
HbAA erythrocytes). It was found that parasitized HbAC 
and HbCC erythrocytes had reduced levels of surface 
PfEMP-1 [105], despite displaying a normal amount of 
another parasite-expressed membrane associated pro-
tein; knob-associated histidine-rich protein (KHARP) 
[63]. Additional molecular studies indicate that parasite 
protein trafficking across the parasitophorous vacuole 
is impaired within HbAC and HbAS cells, and parasites 
growing within these cells form aberrant Maurer’s clefts. 
Together, these impairments may inhibit PfEMP-1 traf-
ficking to the erythrocyte membrane, and explain the 
reduced cytoadherence of these cells [68, 69].
In contrast, SAO parasitized erythrocytes have been 
shown to display an increased affinity for the endothe-
lial host receptor CD36 under flow conditions [107]. 
Although this seems contradictory to the known protec-
tive effect of SAO during severe malaria, it is worth not-
ing that CD36 is an important immune cell receptor, and 
has been implicated in the binding and removal of para-
sitized erythrocytes by both platelets [108] and phago-
cytic cells [109]. The exact effects of increased CD36 
affinity in determining resistance to malaria in SAO 
remain to be determined.
Erythrocyte disorders that modify the cytoadher-
ent properties of infected cells may result in not only 
increased immune cell recognition, but also advanta-
geously reduce blood vessel obstruction, coagulation, 
and inflammation. While good evidence implicates this 
protective mechanism in the aforementioned disorders, 
investigations of other erythrocyte abnormalities associ-
ated with malaria resistance remain to be undertaken.
Erythrocyte senescence
Erythrocytes undergo several age-related physiological 
changes during their normal lifespan, which eventually 
trigger their phagocytosis and recycling by macrophages. 
This senescence is characterized by cell shrinkage, 
increased density and rigidity, and changes to erythro-
cyte surface proteins. Two major models for erythrocyte 
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senescence are commonly reported in the literature. In 
the first model, here referred to as “band 3 senescence”, 
a build-up of haemichromes (products of haemoglobin 
degradation) results in crosslinking between cytoplasmic 
domains of band 3 proteins and formation of aggregates 
[110, 111]. Aggregation is facilitated by phosphoryla-
tion of band 3, another hallmark of senescence, which 
reduces its affinity for the cytoskeletal protein, ankyrin, 
and increases its mobility in the membrane [112]. Aggre-
gated band 3 is recognized by naturally occurring anti-
bodies, which in turn promotes complement protein 
C3 binding and activation [111]. This finally results in 
complement-mediated phagocytosis of the senescent cell 
[113]. The second model, referred to here as “eryptosis”, 
is characterized by increased intracellular calcium, acti-
vation of proteases and phosphatidylserine (PS) expo-
sure on the external surface of the plasma membrane; the 
term eryptosis recognizes that these features are shared 
with apoptosis in nucleated mammalian cells [114]. PS 
exposure leads to phagocytosis of the eryptotic cell [115]. 
Both eryptosis and band 3 senescence are elevated in 
parasitized erythrocytes [93, 116–118], and in direct cor-
relation with increasing parasite maturation [116, 119]. 
An increased oxidative burden imparted on the cell by 
the parasite is believed to be a central cause of these phe-
nomena [116, 119]. Naturally occurring antibodies to 
band 3 are associated with improved malaria outcome, 
indicating that accelerated band 3 senescence may be an 
important contributor to host defence [120].
In several of the haemoglobinpathies, aberrant hae-
moglobin is thought to contribute towards the build-up 
of haemichromes in erythrocytes, thereby accelerating 
band 3 aggregation [121]. In ring stage infected eryth-
rocytes, senescence of HbAS, HbH, and beta thalassae-
mic cells occurs more rapidly than equivalently infected 
normal erythrocytes [122]. This renders ring stage para-
sites within these cells more susceptible to phagocytosis, 
which could contribute toward the resistance phenotype 
conveyed by these disorders. Eryptosis is also enhanced 
in HbAS and beta thalassaemia [123, 124], and contrib-
utes to the early clearance of parasitized cells through PS 
exposure and phagocytosis [125].
Glucose-6-phosphate dehydrogenase (G6PDH) is a 
key enzyme involved in controlling oxidative stress in 
the erythrocyte. Polymorphisms in the X-linked G6PDH 
gene that result in reduced enzyme activity are relatively 
frequent in malaria afflicted populations, and there is 
good evidence that these variants are associated with a 
decreased risk of severe malaria [3, 126–128]. While early 
investigations on the potential protective mechanism 
reported that parasite growth is impaired within G6PD 
deficient erythrocytes [129, 130], this was not supported 
by more recent studies [131]. Instead, it seems more likely 
that elevated oxidative stress in the erythrocyte results in 
increased haemichrome formation, which results in an 
increased susceptibility of ring stage parasitized cells to 
senescence and phagocytosis [131]. G6PD deficient eryth-
rocytes are also more susceptible to eryptosis, which may 
be an additional factor mediating their early clearance 
when parasitized [124]. Genetic-based deficiencies of 
pyruvate kinase (PK), a glycolytic enzyme involved in the 
production of ATP, have been associated with reduced sus-
ceptibility to both rodent and human malaria [132, 133]. 
Similar to G6PD deficiency, increased oxidative stress 
in these defective erythrocytes is thought to accelerate 
ring stage erythrocyte senescence, resulting in enhanced 
phagocytic clearance of parasites [134]. It has also been 
recently reported that parasitized O-blood group erythro-
cytes display increased susceptibility to band 3 senescence 
and phagocytosis, indicating that this mechanism may be 
responsible for the increased malaria resistance that has 
been observed for people of O-blood type [135, 136].
Integrated mechanisms
This review has described a number of ways in which 
erythrocyte disorders may be advantageous to host dur-
ing malarial infection. It is notable that in several cases 
multiple mechanisms have been attributed to a sin-
gle disorder (Table  1). It should also be considered that 
these effects are not mutually exclusive, although in some 
cases they may be closely linked. A good example of this 
is HbAS. In this condition, parasite growth is believed to 
be inhibited in HbAS cells by the actions of both micro 
RNAs [70], aberrant actin remodelling [68], and impaired 
protein trafficking across the parasitophorous vacuole 
[69]. These mechanisms may also explain the reduced 
surface expression of PfEMP-1 and associated reduction 
in cytoadherence [104]. Simultaneously, elevated levels 
of oxidized haemoglobin in HbAS cells leads to increased 
deposition of haemichromes on band 3 [122], causing 
accelerated senescence characterized by band 3 aggrega-
tion and binding of naturally occurring antibodies and 
complement to the erythrocyte surface. The combination 
of decreased cytoadherence and increased opsonization 
collectively results in increased phagocytosis of para-
sitized cells [122]. In addition, increased uptake of para-
sitized erythrocytes may lead to improved presentation 
of surface antigens, resulting in the improved antibody 
response against PfEMP-1 and other parasite surface 
antigens observed in HbAS individuals [137–139]. Anti-
bodies against PfEMP-1 may further inhibit cytoadher-
ence and facilitate phagocytosis in subsequent infections, 
which may explain why the protective effect of HbAS 
increases with age [140, 141] (Figure 1).
It is also plausible that multiple interacting mechanisms 
involving growth, cytoadherence, and senescence may be 
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the basis for malaria resistance in other erythrocyte dis-
orders. For example, erythrocyte senescence is reported 
to be accelerated in G6PD deficiency [131], and similar 
to HbAS cells, increased levels of haemichromes due to 
oxidative stress are also observed [142]. But it is not yet 
known if these abnormalities interfere with protein traf-
ficking in the parasite, or concomitantly, its cytoadherent 
properties. This may also be the case for other disorders 
where erythrocyte oxidative stress is affected. Interest-
ingly, an early study indicated that parasitized HbAE and 
HbEE erythrocytes show an increased susceptibility to 
phagocytosis, however the mechanism behind this was 
not determined [143]. Given the similarities between 
HbAE and the other haemoglobinopathies it would be of 
interest to determine if analogous mechanisms involving 
senescence are responsible for this phenotype.
Implications for malaria treatment
The aforementioned mechanisms of malaria resistance 
conveyed by erythrocyte disorders, particularly those 
involving invasion, have highlighted several potential 
parasite proteins suitable for therapeutic targeting. As 
discussed below, many of these are being developed as 
potential vaccine targets. An alternate, less conventional 
approach is the development of host directed therapies 
(HDTs), which could potentially be designed to mimic 
the protective effects exhibited by naturally occur-
ring erythrocyte disorders. While targeting the parasite 
directly is less likely to cause off target effects due to the 
inherent differences between parasite and human biol-
ogy, it is hampered by substantial variability between 
parasite strains, and the remarkable ability of parasites 
to rapidly mutate and develop drug resistance. HDTs 
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Figure 1 Multiple mechanisms of resistance in sickle cell trait (HbAS). Increased oxidative stress and host microRNAs in HbAS erythrocytes inhibit 
normal parasite development (1). This leads to inhibition of parasite transcription and protein expression (2). The formation of Maurer’s clefts is 
impaired due to aberrant actin morphology, which prevent normal protein trafficking (3). Binding of parasite proteins which reach the erythrocyte 
membrane is inhibited by haemichromes, resulting in reduced surface expression of PfEMP (4). Reduced PfEMP expression results in less cytoad-
herence, which results in increased susceptibility to splenic clearance via phagocytosis (5). Oxidative stress also results in increased haemachrome 
formation (6), inducing band 3 mediated senescence and phagocytosis (7). Enhanced phagocytosis promotes an immune response (8). Increased 
production of antibodies against parasite proteins further inhibits cytoadherence and amplifies the effect (9).
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could potentially avoid this problem, as manipulation of 
the therapeutic target would be outside of direct para-
site genetic control. Indeed, erythrocyte disorders have 
imparted malaria resistance consistently for thousands of 
years, as opposed to parasite directed antimalarials, some 
of which have lost effectiveness after as little as 2–3 years 
of wide-spread use [144]. A caveat to this is that HDTs 
would be at risk of reproducing the deleterious effects 
sometimes associated with erythrocyte disorders, 
although if designed correctly HDTs should theoretically 
be able to avoid this. In fact, many erythrocyte disor-
ders have little or no clinical symptoms, and yet provide 
substantial resistance to malaria infection. Additionally, 
HDTs would only affect the host during short-term treat-
ment regimes, as opposed to genetic mutations, which 
must be tolerated for life. In this review, four major 
mechanisms have been described by which erythrocyte 
disorders can convey malaria resistance. Each of these 
mechanisms could potentially be exploited therapeuti-
cally, either through conventional targeting of parasite 
proteins, or through HDT.
One strategy is to block erythrocyte receptor inter-
actions required for merozoite invasion, either using 
vaccines or small molecules. For P. vivax, protein struc-
ture–function studies have pinpointed the Duffy-antigen 
binding site of PvDBP to a specific domain called PvDB-
PII [145], and development of PvDBPII as a vaccine is 
underway [146]. However, this approach may be chal-
lenging due to significant variability in PvDBPII observed 
amongst different P. vivax isolates [147]. More recently, 
an X-ray crystal structure of the Duffy-PvDBPII com-
plex has been determined, which may help to identify 
conserved, critical binding sites suitable for therapeu-
tic targeting [148]. Studies with Plasmodium knowlesi, 
which also invades erythrocytes via interactions with 
the Duffy receptor [149], have shown that a Duffy bind-
ing chemokine, melanoma growth stimulating activity 
(MGSA), can block merozoite invasion by this parasite 
[150]. Furthermore, as MGSA also binds to type B IL-8 
receptor (IL-8RB) and activates neutrophils [151], a 
mutant form of MGSA was identified that was able to 
inhibit P. knowlesi invasion without cross-reacting with 
IL-8RB [152]. This result highlights the potential of 
developing small molecule inhibitors which specifically 
block the merozoite binding site of the Duffy receptor 
while avoiding off-target effects, and a screen for these 
inhibitors has been proposed [153].
Several invasion blocking vaccines for P. falciparum 
are under development. Many are based on the interac-
tions originally identified through the study of naturally 
occurring erythrocyte disorders, such as the glycophorin 
deficiencies. Vaccines against the P. falciparum mero-
zoite glycophorin binding ligands, PfEBL-1, PfEBA-140 
and PfEBA-175 are all under development [22, 154–156]. 
However, the discovery of glycophorin independent inva-
sion pathways, including CR1-PfRh4 [26] and GYPA-
band 3-RhopH3-MSP1 [157], will likely complicate the 
effectiveness of such approaches. A more ideal vaccine 
target in this respect may be the basigin-PfRh5 interac-
tion. Antibodies targeting this complex have been shown 
to completely block erythrocyte invasion by all P. falci-
parum strains tested to date [29, 158, 159]. Preliminary 
studies have also have indicated that vaccine induced 
antibodies to PfRh5 inhibit the growth of PfRh5 poly-
morphic P. falciparum strains in  vitro [158, 160], and 
PfRh5 vaccinated Aotus monkeys were protected from 
experimental infection [161]. In terms of HDTs, antibody 
blocking of basigin as opposed to PfRh5 has been dem-
onstrated to be more efficacious in preventing invasion 
[28, 162]. This is possibly due to the fact that merozoite 
antigens are only exposed for seconds while erythrocyte 
receptors are continuously exposed, allowing binding to 
reach equilibrium [162]. Mimicking protective cytoskele-
tal abnormalities is also an appealing, but probably more 
challenging approach. However, artificial inhibition of 
band 3 mobility has already been demonstrated to pre-
vent merozoite invasion [53], opening up the possibility 
of achieving this in a clinically relevant manner.
The parasite depends on a wide range of host factors 
in order to facilitate its development and survival within 
the erythrocyte, and natural protective mechanisms that 
affect such factors indicate a number of potential targets. 
In some cases inhibitors for such factors have already 
been developed, and preclinical efficacy demonstrated. 
For example, G6PD deficiency is known to reduce malaria 
susceptibility, and recent chemical screens have identified 
inhibitors for both human G6PD [163], and P. falciparum 
G6PD [164], with the later demonstrated to reduce para-
site growth in vitro. Inhibitors for the host kinase MEK1 
have also shown anti-malarial properties, and it has been 
suggested these compounds may act against the parasite 
in a host directed manner [85]. Erythrocyte enzymes that 
are imported by the parasite have also been examined as 
potential antimalarial targets. Studies have shown that 
the parasite imports and utilizes the host erythrocyte 
enzyme Fech [165], and that the parasite-expressed Fech 
is dispensable [79]. More recently it was demonstrated 
that parasite growth is reduced in both mouse and 
human erythrocytes with reduced Fech activity, and that 
a Fech inhibitor N-methylprotoporphyrin completely 
prevented parasite growth in  vitro [84]. Taken together, 
this suggests that anti-Fech agents can act against the 
parasite in a host directed manner. In another example, 
parasite growth is blocked in erythrocytes treated with 
an irreversible inhibitor of peroxiredoxin [166]; the para-
site normally imports and utilizes host peroxiredoxin-2 
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during its development [89]. Sotrastaurin is a PKC inhib-
itor that is currently undergoing Phase II clinical trials 
for the treatment of psoriasis and in liver transplant [167, 
168]. The drug is also highly protective in mice infected 
with Plasmodium berghei and P. yoelii, and inhibits P. fal-
ciparum growth in  vivo [87]. Interestingly, no parasite 
orthologue for the PKC enzyme exists, suggesting the 
drug may act in a host-directed manner against erythro-
cyte PKC.
Cytoadherence of infected erythrocytes is another 
attractive therapeutic target, given it has been implicated 
in the resistance mechanisms of several erythrocyte dis-
orders. Fucosylated chondroitin sulfate was found to 
inhibit cytoadherence to human lung endothelial cells 
by P. falciparum infected erythrocytes, including clinical 
isolates, highlighting its potential therapeutic value [169]. 
The anthelmintic drug levamisole hydrochloride has 
been shown to reduce cytoadherence of infected eryth-
rocytes to CD36 [170], however, in a recent randomized 
controlled trial no clinical benefit was gained when given 
as an adjuvant to artesunate [171]. This result may indi-
cate that CD36 binding is not detrimental during malaria 
infection, a notion supported by the fact that the malaria 
protective condition SAO enhances CD36 binding [107]. 
In another study, erythrocyte casein kinase II, which 
is involved in phosphorylation of PfEMP-1, has been 
pharmacologically inhibited to reduce cytoadherence of 
infected erythrocytes [172].
Erythrocyte senescence has also proven to be a prac-
tical antimalarial target, and compounds designed to 
accelerate this process have shown potential, with several 
producing protective effects during the course of malaria 
infection. These include chlorpromazine [173], paclitaxel 
[174], the NO synthase inhibitor L-NAME [175], the hor-
mone analogue 16 alpha-bromoepiandrosterone [176], 
and, indolone-N-oxides [177]. The later are currently 
undergoing clinical trials for their antimalarial activ-
ity. As these compounds induce oxidative stress in the 
erythrocyte, it would be of interest to determine if they 
may concurrently inhibit parasite protein trafficking and 
reduce cytoadherence, as is demonstrated for erythro-
cyte disorders such as sickle cell trait.
Conclusions
Studies of erythrocytic genetic disorders associated 
with host resistance to malaria have arguably been the 
most important source of knowledge regarding the 
Plasmodium-erythrocyte interaction to date. These 
studies have not only facilitated the discovery of many 
of the host-parasite protein interactions involved in 
merozoite invasion of erythrocytes, but have also pro-
vided clues as to what host factors are important for 
the intraerythrocytic development of the parasite. It is 
a testament to the complexity of this delicate interac-
tion that even after nearly 70 years of research, entirely 
new mechanisms for host resistance in conditions such 
as sickle cell trait, as well as completely novel host-par-
asite receptor interactions, are being elucidated. Indeed, 
much about the Plasmodium-erythrocyte interaction 
in erythrocytic genetic disorders remains unclear. As 
parasite resistance to antimalarials becomes increas-
ingly prevalent, the development of novel therapies will 
be more important than ever. Research into the mecha-
nisms of resistance provided by erythrocyte disorders 
is highlighting the key factors required for parasite 
survival, and the potential for targeting these thera-
peutically, both through conventional parasite-directed 
treatments, or through HDT.
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